Kovitz Investment Group Partners LLC Cuts Position in Abbott Laboratories $ABT

Kovitz Investment Group Partners LLC trimmed its holdings in shares of Abbott Laboratories (NYSE:ABT) by 98.0% in the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 20,951 shares of the healthcare product maker’s stock after selling 1,052,608 shares during the period. Kovitz Investment Group Partners LLC’s holdings in Abbott Laboratories were worth $2,625,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. MidAtlantic Capital Management Inc. purchased a new stake in Abbott Laboratories during the 4th quarter valued at about $25,000. Cornerstone Financial Management LLC purchased a new position in shares of Abbott Laboratories in the fourth quarter worth $25,000. Portfolio Resources Advisor Group Inc. bought a new stake in Abbott Laboratories in the 4th quarter worth about $26,000. Abound Financial LLC bought a new position in Abbott Laboratories during the 4th quarter valued at about $26,000. Finally, Harbor Capital Advisors Inc. bought a new stake in shares of Abbott Laboratories in the fourth quarter worth approximately $27,000. Institutional investors own 75.18% of the company’s stock.

Insiders Place Their Bets

In other Abbott Laboratories news, Director Daniel J. Starks purchased 10,000 shares of the firm’s stock in a transaction on Monday, April 27th. The shares were acquired at an average cost of $92.65 per share, with a total value of $926,500.00. Following the completion of the acquisition, the director directly owned 6,751,103 shares in the company, valued at $625,489,692.95. The trade was a 0.15% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CFO Philip P. Boudreau acquired 2,200 shares of the company’s stock in a transaction dated Thursday, April 23rd. The stock was acquired at an average cost of $91.50 per share, with a total value of $201,300.00. Following the purchase, the chief financial officer owned 2,200 shares of the company’s stock, valued at approximately $201,300. This trade represents a ∞ increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Corporate insiders own 0.46% of the company’s stock.

Abbott Laboratories Price Performance

NYSE ABT opened at $88.48 on Friday. The business’s fifty day moving average is $90.08 and its 200 day moving average is $106.60. Abbott Laboratories has a fifty-two week low of $81.97 and a fifty-two week high of $139.06. The company has a debt-to-equity ratio of 0.56, a quick ratio of 1.01 and a current ratio of 1.39. The company has a market capitalization of $154.12 billion, a PE ratio of 24.78, a price-to-earnings-growth ratio of 1.52 and a beta of 0.63.

Abbott Laboratories (NYSE:ABT) last posted its quarterly earnings data on Thursday, April 16th. The healthcare product maker reported $1.15 EPS for the quarter, topping the consensus estimate of $1.14 by $0.01. Abbott Laboratories had a return on equity of 17.62% and a net margin of 13.90%.The firm had revenue of $11.16 billion for the quarter, compared to the consensus estimate of $10.99 billion. During the same quarter last year, the company earned $1.09 earnings per share. The business’s revenue for the quarter was up 7.8% compared to the same quarter last year. Abbott Laboratories has set its FY 2026 guidance at 5.380-5.580 EPS and its Q2 2026 guidance at 1.250-1.310 EPS. Sell-side analysts predict that Abbott Laboratories will post 5.48 earnings per share for the current year.

Abbott Laboratories Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, August 17th. Investors of record on Wednesday, July 15th will be issued a $0.63 dividend. The ex-dividend date of this dividend is Wednesday, July 15th. This represents a $2.52 annualized dividend and a yield of 2.8%. Abbott Laboratories’s dividend payout ratio is currently 70.59%.

Analyst Ratings Changes

ABT has been the topic of several research reports. Wells Fargo & Company dropped their target price on shares of Abbott Laboratories from $122.00 to $109.00 and set an “overweight” rating on the stock in a report on Friday, April 17th. JPMorgan Chase & Co. cut their price objective on Abbott Laboratories from $123.00 to $110.00 and set an “overweight” rating for the company in a report on Friday, April 17th. Weiss Ratings downgraded Abbott Laboratories from a “hold (c-)” rating to a “sell (d+)” rating in a report on Tuesday. Barclays dropped their target price on Abbott Laboratories from $144.00 to $143.00 and set an “overweight” rating on the stock in a research report on Monday, April 20th. Finally, Bank of America reduced their price target on shares of Abbott Laboratories from $120.00 to $102.00 in a research report on Friday, June 12th. Two equities research analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $118.30.

About Abbott Laboratories

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.